September 20, 2010 10:08 ET

Biologics Industry Expected to Grow 9.3% Between 2009 and 2016

ROCKVILLE, MD--(Marketwire - September 20, 2010) - has announced the addition of GBI Research's new report "Manufacturing of Biologics -- Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies" to their collection of Pharmaceuticals market reports. For more information, visit

The biologics industry has emerged as a major growth area in the global healthcare industry. Since its emergence in the 1970s, the biologics industry has grown rapidly to reach approximately $128 billion in 2009. GBI Research's analysis suggests that the biologics drugs market has outperformed the pharmaceutical market in the past few years. The biologics industry had a year on year average growth rate of approximately 11.5% over the period of 2007-2009. This is significantly higher than the pharmaceutical industry's growth rate of 6% in the same time period. It is expected to grow by 9.3% for the period of 2009-2016.

According to the report, the use of CMOs is one of the most significant trends in the healthcare industry, especially in the biologics market. CMOs will be used for most of the processes in the industry. Although the CMO market is not growing much at the moment due to capacity expansions by major companies such as Lonza Group Ltd., Boehringer Ingelheim (BI), and many more. Their focus has been shifted towards setting up new plants, buying new equipments. These expansion processes indicate the future prospects of the industry. Many experts in the industry have already predicted that the future of the CMO market is bright. Several players from emerging countries are entering the market. Companies are opening up beginning operations in emerging countries such as India, China, and Singapore.

GBI Research suggests that the CMO biologics market is set to grow at a CAGR of 13.4%, (2009-16) which is faster than the overall CMO market.

The market shares of CMOs in developed countries are expected to decline in the coming years due to the high cost of operations and the development taking place in the emerging markets. The share of the emerging markets is expected to more than double by 2013 and to triple by 2016.

Biologics manufacturing is expected to grow in the near future. Most of the biologics companies are expanding their manufacturing facilities throughout the world. New companies are coming into the market and many pharmaceutical companies are now manufacturing biologics.

Currently, the capacity in the industry is more than the production. The major reasons for this are the low capacity utilization rate and low demand.

GBI Research expects the overall capacity to grow at 10.8% from 2009 to 2013, after which market will stabilize and growth rate will be slower. It is expected that it will grow at the rate of 1.42% over the period of 2013-2016.

For more information, visit

Contact Information